InterCure 과거 수익 실적
과거 기준 확인 0/6
InterCure has been growing earnings at an average annual rate of 1%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 45.1% per year.
주요 정보
1.0%
수익 성장률
10.7%
EPS 성장률
Pharmaceuticals 산업 성장 | 6.0% |
매출 성장률 | 45.1% |
자기자본 수익률 | -14.6% |
순이익 | -24.1% |
최근 수익 업데이트 | 30 Jun 2024 |
최근 과거 실적 업데이트
Recent updates
InterCure: A Cannabis Industry Leader Still Flying Under The Radar
Jun 30InterCure: Bargain Israel Cannabis Play
Apr 22InterCure: A Leader In Global Cannabis
Sep 06InterCure reports Q2 results
Aug 15InterCure Is Growing In The Massive Global Cannabis Market
Jun 07IntureCure: Israel Recreation Cannabis Boom On The Way
Feb 16InterCure Chairman Ehud Barak, CEO Alex Rabinovitch - Israel Cannabis And Beyond (Video)
Nov 08InterCure: Internationally Profitable Cannabis (Podcast Transcript)
Sep 19InterCure: Ignored Uplisting
Sep 09수익 및 비용 분석
InterCure 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
---|---|---|---|---|
30 Jun 24 | 273 | -66 | 93 | 0 |
31 Mar 24 | 312 | -61 | 96 | 0 |
31 Dec 23 | 356 | -62 | 98 | 0 |
30 Sep 23 | 388 | -20 | 103 | 0 |
30 Jun 23 | 415 | 21 | 110 | 1 |
31 Mar 23 | 408 | 32 | 109 | 1 |
31 Dec 22 | 389 | 45 | 102 | 1 |
30 Sep 22 | 363 | 33 | 96 | 1 |
30 Jun 22 | 324 | 24 | 80 | 1 |
31 Mar 22 | 274 | 15 | 67 | 1 |
31 Dec 21 | 220 | 5 | 57 | 1 |
30 Sep 21 | 167 | 17 | 43 | 1 |
30 Jun 21 | 128 | 20 | 35 | 2 |
31 Mar 21 | 94 | 13 | 30 | 2 |
31 Dec 20 | 65 | -37 | 27 | 2 |
30 Sep 20 | 40 | -63 | 26 | 2 |
30 Jun 20 | 20 | -80 | 32 | 2 |
31 Mar 20 | 11 | -91 | 41 | 2 |
31 Dec 19 | 9 | -6 | 83 | 2 |
30 Sep 19 | 7 | 7 | 81 | 1 |
30 Jun 19 | 5 | 18 | 72 | 0 |
31 Mar 19 | 2 | 27 | 58 | 0 |
31 Dec 18 | 0 | -13 | 10 | 0 |
30 Sep 18 | 0 | -10 | 5 | 0 |
30 Jun 18 | 0 | -8 | 1 | 0 |
31 Mar 18 | 0 | -7 | 1 | 0 |
31 Dec 17 | 0 | -6 | 1 | 0 |
30 Sep 17 | 0 | -4 | 1 | 0 |
30 Jun 17 | 0 | -2 | 1 | 0 |
31 Mar 17 | 0 | -2 | 1 | 0 |
31 Dec 16 | 0 | 0 | 1 | 0 |
30 Sep 16 | 0 | 0 | 2 | 0 |
30 Jun 16 | 0 | -1 | 2 | 0 |
31 Mar 16 | 1 | 0 | 2 | 0 |
31 Dec 15 | 1 | -2 | 2 | 0 |
30 Sep 15 | 2 | -1 | 3 | 0 |
30 Jun 15 | 3 | -2 | 3 | 0 |
31 Mar 15 | 4 | -4 | 4 | 0 |
31 Dec 14 | 6 | -4 | 6 | 0 |
30 Sep 14 | 7 | -5 | 6 | 0 |
30 Jun 14 | 7 | -5 | 6 | 0 |
31 Mar 14 | 8 | -6 | 7 | 0 |
31 Dec 13 | 8 | -7 | 8 | 0 |
양질의 수익: INCR is currently unprofitable.
이익 마진 증가: INCR is currently unprofitable.
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: INCR is unprofitable, but has reduced losses over the past 5 years at a rate of 1% per year.
성장 가속화: Unable to compare INCR's earnings growth over the past year to its 5-year average as it is currently unprofitable
수익 대 산업: INCR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
자기자본 수익률
높은 ROE: INCR has a negative Return on Equity (-14.58%), as it is currently unprofitable.